Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anecortave sterile · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Anecortave Acetate | EXPERIMENTAL | Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18) |
| Anecortave Acetate Vehicle | PLACEBO_COMPARATOR | Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18) |
| 15 mg Anecortave Acetate, 3 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months). |
| 15 mg Anecortave Acetate, 6 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months). |
| 30 mg Anecortave Acetate, 6 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months). |
| Anecortave and Sham PDT | ACTIVE_COMPARATOR | - |
| PDT and Sham Anecortave Acetate | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Anecortave Acetate 15 mg sterile suspension | DRUG | 0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection |
| Anecortave Acetate Vehicle | OTHER | Administered as a posterior juxtascleral injection |
| Anecortave Acetate Sterile Suspension, 30 mg/mL | DRUG | One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals |
| Anecortave Acetate Sterile Suspension, 60 mg/mL | DRUG | One 0.5 mL posterior juxtascleral depot injection at 6 month intervals |
| Photodynamic Therapy (PDT) | OTHER | - |
Inclusion Criteria: * Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Under 50 years. * Other protocol-defined exclusion criteria may apply.
Anecortave Sterile,mL is an investigational small molecule being developed by Alcon Inc. for ophthalmology indications, including open-angle glaucoma, eye diseases, and macular degeneration. It has been studied in clinical trials for subfoveal choroidal neovascularization due to wet age-related macular degeneration and for open-angle glaucoma.
Anecortave Sterile,mL is being developed by Alcon Inc., a company traded under the ticker ALC. The drug is an investigational small molecule in the ophthalmology therapeutic area.
Anecortave Sterile,mL is currently in Phase 2 clinical development. It has completed three clinical trials, including one Phase 3 trial for wet age-related macular degeneration and multiple Phase 2 trials for open-angle glaucoma. The drug is investigational and not approved.
Anecortave Sterile,mL has been studied in three completed trials. NCT00051129 was a Phase 3 trial in wet age-related macular degeneration with 291 participants. NCT00320203 and NCT00451152 were Phase 2 trials in open-angle glaucoma, and NCT00691717 was a Phase 2 trial in open-angle glaucoma or ocular hypertension.
Anecortave Sterile,mL is the drug name used in clinical trial records, and the trials refer to the study drug as anecortave acetate. The clinical trials listed under the drug name Anecortave Sterile,mL investigate anecortave acetate as the active agent.
Anecortave Sterile,mL is a small molecule being studied for its effects in ophthalmology conditions such as open-angle glaucoma and macular degeneration. The specific molecular target of the drug has not been disclosed in the available clinical trial information.